137 related articles for article (PubMed ID: 24393871)
21. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.
Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S
Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322
[TBL] [Abstract][Full Text] [Related]
22. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
[TBL] [Abstract][Full Text] [Related]
23. A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer.
Ueki T; Manabe T; Inoue S; Ienaga J; Yamanaka N; Egami T; Ishikawa M; Konomi H; Ikubo A; Nagayoshi K; Nakamura M; Tanaka M
Anticancer Res; 2016 Feb; 36(2):741-7. PubMed ID: 26851033
[TBL] [Abstract][Full Text] [Related]
24. Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer.
Karacetin D; Yalcin B; Okten B; Ozturk S; Maral O; Incekara O
J BUON; 2009; 14(4):605-8. PubMed ID: 20148449
[TBL] [Abstract][Full Text] [Related]
25. Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer.
Larsen FO; Boisen MK; Fromm AL; Jensen BV
Acta Oncol; 2012 Feb; 51(2):231-3. PubMed ID: 21936753
[TBL] [Abstract][Full Text] [Related]
26. Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study.
Leone F; Artale S; Marino D; Cagnazzo C; Cascinu S; Pinto C; Fornarini G; Tampellini M; Di Fabio F; Sartore-Bianchi A; De Carlis L; Pugliese R; Capussotti L; Gioeni L; Siena S; Aglietta M
Cancer; 2013 Oct; 119(19):3429-35. PubMed ID: 23868516
[TBL] [Abstract][Full Text] [Related]
27. A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer.
Puthillath A; Mashtare T; Wilding G; Khushalani N; Steinbrenner L; Ross ME; Romano K; Wisniewski M; Fakih MG
Crit Rev Oncol Hematol; 2009 Sep; 71(3):242-8. PubMed ID: 19081732
[TBL] [Abstract][Full Text] [Related]
28. A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902).
Ogata Y; Shimokawa M; Tanaka T; Emi Y; Oki E; Saeki H; Sadanaga N; Kusumoto T; Touyama T; Kimura M; Baba H; Akagi Y; Shirouzu K; Maehara Y;
Int J Clin Oncol; 2016 Apr; 21(2):335-343. PubMed ID: 26338269
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
Hochster HS; Hart LL; Ramanathan RK; Childs BH; Hainsworth JD; Cohn AL; Wong L; Fehrenbacher L; Abubakr Y; Saif MW; Schwartzberg L; Hedrick E
J Clin Oncol; 2008 Jul; 26(21):3523-9. PubMed ID: 18640933
[TBL] [Abstract][Full Text] [Related]
30. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies.
Lorenz M; Staib-Sebler E; Gog C; Proschek D; Jauch KW; Ridwelski K; Hohenberger W; Gassel HJ; Lehmann U; Vestweber KH; Padberg W; Zamzow K; Müller HH
Zentralbl Chir; 2003 Feb; 128(2):87-94. PubMed ID: 12632273
[TBL] [Abstract][Full Text] [Related]
31. Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer.
Farid M; Chowbay B; Chen X; Tan SH; Ramasamy S; Koo WH; Toh HC; Choo SP; Ong SY
Cancer Chemother Pharmacol; 2012 Jul; 70(1):141-50. PubMed ID: 22648745
[TBL] [Abstract][Full Text] [Related]
32. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases.
Gruenberger B; Scheithauer W; Punzengruber R; Zielinski C; Tamandl D; Gruenberger T
BMC Cancer; 2008 Apr; 8():120. PubMed ID: 18439246
[TBL] [Abstract][Full Text] [Related]
33. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
[TBL] [Abstract][Full Text] [Related]
34. Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
Carrato A; Gallego-Plazas J; Guillén-Ponce C
Expert Rev Anticancer Ther; 2008 Feb; 8(2):161-74. PubMed ID: 18279056
[TBL] [Abstract][Full Text] [Related]
35. A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer.
Sehgal R; Lembersky BC; Rajasenan KK; Crandall TL; Balaban EP; Pinkerton RA; Kane P; Schmotzer A; Zeh H; Potter DM; Ramanathan RK
Clin Colorectal Cancer; 2011 Jun; 10(2):117-20. PubMed ID: 21859564
[TBL] [Abstract][Full Text] [Related]
36. [Second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer after resection of the primary lesion].
Abe H; Mafune K; Minamimura K; Abe M; Umemura A; Hirata T
Gan To Kagaku Ryoho; 2013 May; 40(5):601-4. PubMed ID: 23863581
[TBL] [Abstract][Full Text] [Related]
37. Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial).
Martoni AA; Pinto C; Di Fabio F; Lelli G; Rojas Llimpe FL; Gentile AL; Mutri V; Ballardini P; Giaquinta S; Piana E
Eur J Cancer; 2006 Dec; 42(18):3161-8. PubMed ID: 17098421
[TBL] [Abstract][Full Text] [Related]
38. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
Porschen R; Arkenau HT; Kubicka S; Greil R; Seufferlein T; Freier W; Kretzschmar A; Graeven U; Grothey A; Hinke A; Schmiegel W; Schmoll HJ;
J Clin Oncol; 2007 Sep; 25(27):4217-23. PubMed ID: 17548840
[TBL] [Abstract][Full Text] [Related]
39. Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: the CORGI-L Study.
Gunnlaugsson A; Anderson H; Fernebro E; Kjellén E; Byström P; Berglund K; Ekelund M; Påhlman L; Holm T; Glimelius B; Johnsson A
Eur J Cancer; 2009 Mar; 45(5):807-13. PubMed ID: 19110416
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer.
Vrdoljak E; Omrčen T; Boban M; Hrabar A
Anticancer Drugs; 2011 Feb; 22(2):191-7. PubMed ID: 21057306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
